Aquestive Therapeutics (Formerly known as MonoSolRx)
1701 County Line Road
Portage
Indiana
46368
United States
Tel: 219-762-3165
Website: http://www.monosol.com/
Email: film@monosol.com
260 articles about Aquestive Therapeutics (Formerly known as MonoSolRx)
-
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8/7/2023
Aquestive Therapeutics, Inc. (NASDAQ:AQST) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent developments in its business.
-
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
8/2/2023
Aquestive Therapeutics, Inc. announced today that the management team will participate in the 2023 Wedbush PacGrow Healthcare Conference in New York.
-
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
7/27/2023
Aquestive Therapeutics, Inc. today released topline data from its latest clinical crossover pilot trial, Study AQ109103 (the “103 study”), for Anaphylm™ (epinephrine) Sublingual Film.
-
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
7/25/2023
Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”) today announced that it will report results for the second quarter ended June 30, 2023, and provide an update on recent developments in its business after market close on Monday, August 7, 2023.
-
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
7/25/2023
Aquestive Therapeutics, Inc. today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO.
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
7/6/2023
Aquestive Therapeutics, Inc. today announced that two posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm epinephrine sublingual film will be presented at the Global Food Allergy Prevention Summit (GFAPS 2023), which will be held from July 7-9 in Chicago, IL.
-
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
6/29/2023
Aquestive Therapeutics, Inc. today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company.
-
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
5/31/2023
Aquestive Therapeutics, Inc. released topline clinical data from recent pilot studies that were completed following the End-of-Phase 2 meeting with the FDA.
-
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
5/2/2023
Aquestive Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.
-
Aquestive Therapeutics to Participate in Two Upcoming May 2023 Investor Conferences
4/26/2023
Aquestive Therapeutics, Inc. announced that the management team will participate in two upcoming investor conferences as follows.
-
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
4/20/2023
Aquestive Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Anaphylm™ as the proposed brand name for AQST-109, the Company’s polymer matrix-based epinephrine prodrug administered as a sublingual film in development for the treatment of severe allergic reactions including anaphylaxis.
-
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
4/18/2023
Aquestive Therapeutics, Inc. today announced that it will report results for first quarter ended March 31, 2023, and provide an update on recent developments in its business after market close on Tuesday, May 2, 2023.
-
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
3/29/2023
Aquestive Therapeutics, Inc. today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited.
-
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
3/7/2023
Aquestive Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a progress update on the key 2023 objectives previously outlined by the Company.
-
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
3/1/2023
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to March 15th.
-
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
2/22/2023
Aquestive Therapeutics, Inc. today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023.
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
2/21/2023
Aquestive Therapeutics, Inc. today announced that four late breaking posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of AQST-109 epinephrine sublingual film will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting, which will be held from February 24-27 in San Antonio, Texas.
-
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
1/6/2023
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives.
-
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
12/22/2022
Aquestive Therapeutics, Inc. today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.
-
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
11/29/2022
Aquestive Therapeutics, Inc. announced the publication of a crossover food effect pharmacokinetic study of diazepam nasal spray in the peer-reviewed scientific journal Epilepsia.